ALTON JONES CELL SCIENCE CENTE has a total of 18 patent applications. Its first patent ever was published in 1989. It filed its patents most often in United States, Australia and EPO (European Patent Office). Its main competitors in its focus markets biotechnology, pharmaceuticals and machines are IMMUNETECH PHARMACEUTICALS, GOOD BIOTECH CORP and INT GENETIC ENG.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 11 | |
#2 | Australia | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | WIPO (World Intellectual Property Organization) | 2 | |
#5 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Machines |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Unspecified technologies | |
#4 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Serrero Ginette | 13 |
#2 | Colburn Patricia C | 3 |
#3 | Buonassisi Vincenzo | 3 |
#4 | Sato J Denry | 2 |
#5 | Okamoto Tetsuji | 1 |
#6 | Wang Lihua | 1 |
#7 | Myoken Yoshinari | 1 |
#8 | Wu Dianging | 1 |
Publication | Filing date | Title |
---|---|---|
US5449757A | Mammalian adipogenic factors | |
US5723115A | Inhibition of adipose tissue development and obesity | |
US5459061A | Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor | |
CA2128323A1 | Mammalian adipogenic factors | |
US5219994A | Inhibitor of tissue factor activity | |
AU8087591A | Mammalian adipogenic factors | |
US5268295A | Mammalian adipocyte protein p154, nucleic acids coding therefor and uses thereof | |
US5110737A | Method for the isolation of hybridomas using cholesterol auxotrophy of myeloma cells |